Sunesis Pharmaceuticals (SNSS) Cut to “Strong Sell” at Zacks Investment Research
Sunesis Pharmaceuticals (NASDAQ:SNSS) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Wednesday.
According to Zacks, “Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. “
A number of other brokerages have also commented on SNSS. Cantor Fitzgerald reissued a “hold” rating and set a $4.00 price objective on shares of Sunesis Pharmaceuticals in a report on Thursday, March 8th. ValuEngine lowered Sunesis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Oppenheimer assumed coverage on Sunesis Pharmaceuticals in a report on Thursday, December 14th. They set a “buy” rating and a $7.00 price objective on the stock. UBS Group assumed coverage on Sunesis Pharmaceuticals in a report on Monday, November 20th. They set an “outperform” rating on the stock. Finally, Wells Fargo & Co lowered Sunesis Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $2.70 to $2.00 in a report on Tuesday, December 5th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $4.00.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last issued its quarterly earnings data on Thursday, March 8th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.08. analysts expect that Sunesis Pharmaceuticals will post -1.01 earnings per share for the current year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in SNSS. Wells Fargo & Company MN grew its holdings in Sunesis Pharmaceuticals by 77.4% in the 2nd quarter. Wells Fargo & Company MN now owns 41,851 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 18,254 shares during the last quarter. Geode Capital Management LLC grew its holdings in Sunesis Pharmaceuticals by 105.2% in the 4th quarter. Geode Capital Management LLC now owns 125,489 shares of the biopharmaceutical company’s stock valued at $463,000 after buying an additional 64,343 shares during the last quarter. BlackRock Inc. grew its holdings in Sunesis Pharmaceuticals by 9.5% in the 4th quarter. BlackRock Inc. now owns 130,573 shares of the biopharmaceutical company’s stock valued at $482,000 after buying an additional 11,351 shares during the last quarter. Vatera Holdings LLC acquired a new stake in Sunesis Pharmaceuticals in the 4th quarter valued at approximately $673,000. Finally, Vanguard Group Inc. grew its holdings in Sunesis Pharmaceuticals by 4.1% in the 2nd quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock valued at $1,635,000 after buying an additional 23,819 shares during the last quarter. 53.20% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/03/14/sunesis-pharmaceuticals-snss-cut-to-strong-sell-at-zacks-investment-research.html.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.